About Radyus
We’re a team of experienced drug developers with pharma R&D and venture capital backgrounds. We know what good looks like to buyers and investors when developing a new drug. Our services are designed to guide our clients to success and expedite drug development.
We work with biotech companies, academic startups, and venture capital firms.
Most frequently we partner with our clients at a lead optimization and candidate selection stage, through IND-enabling studies and into first in human trials.
Our expertise is in immunology, oncology, infectious diseases, metabolic diseases, and neurosciences - across modalities.
Our Team
-
Marta New, PhD, MBA
Chief Executive Officer
-
Anthony Chilton, PhD
Chief Operating Officer
-
Eric Springman, PhD
Head of Development
-
David Ford, PhD, PMP
Sr. Director, PM
-
Jen Schireiber, PhD, PMP
Sr. BD Lead
-
Abigail (Abby) Cannon, PhD
Project Lead
-
Alan Benjamin Frey, PhD
Scientific Development
-
Dave Edwards, CBIOL, MRSB
Toxicology Lead
-
Caitlin J. Couch (Risener), Phd
Operations Manager
-
Lucy Outtrim, PhD Candidate
Research Associate
Board of Directors
-
Paul Tebbey, PhD
Co-Founder
-
Jane McCracken
CRO Operations
-
Anna Walz
BD Strategy
Scientific Advisory Board
-
Dennis Liotta, PhD
Anti-Infectives
-
Mark Shlomchik, MD, PhD
Immunology
-
Laura Soucek, PhD
Oncology
-
Richard B. Silverman, PhD
CNS/Neuro
-
Frederick (Rick) Sax, MD
Cardiometabolic
Industry Advisory Board
-
Eric Rowinsky, MD
Clinical Development
-
John M. Sall, PharmD, PhD
Regulatory Strategy
-
Sasha Khursheed Said, BA
Sales Strategy
-
Anne Horgan, PhD
Venture Capital
-
Ted B. Leggett, MS
Quality
-
Russell B. Allen, BA
Commercialization
-
David Day, BA
University Relations and Licensing
-
Priyanka Rohatgi, PhD
Venture Capital & Business Development